Fill-finish Pharmaceutical Contract Manufacturing Market Size & Share 2024 - 2032

Fill-finish Pharmaceutical Contract Manufacturing Market Size

Fill-finish Pharmaceutical Contract Manufacturing Market was valued at USD 7.7 billion in 2023 and is anticipated to grow at a CAGR of 6.2% between 2024 – 2032. One of the primary drivers is the increasing demand for biopharmaceuticals and parenteral drugs, that require specialized filling and finishing processes.

Additionally, the rise in outsourcing of pharmaceutical manufacturing by pharmaceutical companies to reduce costs and focus on core competencies is boosting the demand for contract manufacturing services. Moreover, the complexity of drug formulations and the need for advanced technologies and expertise in aseptic filling and finishing are also fueling market growth. Furthermore, the growing prevalence of chronic diseases and the need for novel drug delivery systems are contributing to the expansion of the market.
 

Fill-finish pharmaceutical contract manufacturing refers to the process of filling drug products into their final dosage form (such as vials, syringes, or cartridges) and finishing them for distribution. This process is crucial for ensuring the safety, efficacy, and quality of pharmaceutical products. Contract manufacturing organizations (CMOs) specialize in fill-finish services, offering expertise in aseptic processing, sterile filling, lyophilization (freeze-drying), and packaging.

Fill-finish Pharmaceutical Contract Manufacturing Market Trends

• Pharmaceutical companies are increasingly turning to contract manufacturers to streamline their operations, reduce costs, and enhance flexibility in response to changing market demands.
   
• Outsourcing fill-finish services allows companies to focus on their core competencies such as research and development, while leveraging the specialized expertise and infrastructure of contract manufacturers for the final stages of production.
   
• This trend is particularly pronounced in the biopharmaceutical sector, where the complexity of manufacturing processes and the need for specialized facilities have made outsourcing an attractive option.
   
• As a result, the fill-finish pharmaceutical contract manufacturing industry is expected to experience robust growth in the coming years, driven by the increasing adoption of outsourcing strategies by pharmaceutical companies.
   

Fill-finish Pharmaceutical Contract Manufacturing Market Analysis

Based on product, the market is segmented into vials, prefilled syringes (PFS), cartridges, and other products. The vials segment is further divided into glass vials and plastic vials. The vials segment dominated the market is 2023 and accounted for USD 4.1 billion.
 

• Vials are a preferred packaging option for many pharmaceutical products due to their durability, sterility, and ease of use. They are commonly used for packaging injectable drugs, vaccines, and biologics, making them essential in the pharmaceutical industry.
   
• Additionally, advancements in vial manufacturing technologies, such as improved materials and design, have enhanced their quality and usability, contributing to their significant market share.
   
• Hence, the vials segment is expected to continue its growth trajectory, fueled by the rising demand for parenteral drugs and the expanding pharmaceutical contract manufacturing industry.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on molecule, the fill-finish pharmaceutical contract manufacturing market is segmented into large molecules and small molecules. The large molecules segment dominated the market with 67% of market share in 2023.
 

• Large molecules, such as proteins and monoclonal antibodies, are increasingly being used in pharmaceuticals for their efficacy in treating complex diseases. As these molecules are more fragile and require specialized handling and manufacturing processes, pharmaceutical companies often turn to contract manufacturing organizations (CMOs) with expertise in large molecule fill-finish services.
   
• This has driven significant growth in the demand for fill-finish services for large molecules, leading to the segment's high market share.
   
• Additionally, the rise in biopharmaceutical development and the increasing adoption of biologics have further fueled the demand for fill-finish services for large molecules, solidifying the segment's prominent position in the market.
   

Based on end-use, the market is categorized into biopharmaceutical companies and pharmaceutical companies. The biopharmaceutical companies segment dominated the market in 2023 and is predicted to grow at CAGR of 5.9% over the forecast period.
 

• Biopharmaceutical companies often outsource fill-finish operations to contract manufacturers to leverage their specialized expertise, infrastructure, and regulatory compliance. This allows biopharmaceutical companies to focus on core competencies such as drug development and commercialization.
   
• Additionally, the increasing complexity of biologic drugs requires specialized manufacturing capabilities that many biopharmaceutical companies prefer to access through contract manufacturers.
   
• Further, the market share of biopharmaceutical companies in this segment is expected to remain strong due to the growing demand for biologic drugs and the trend towards outsourcing non-core activities to improve operational efficiency and reduce costs.
   

North America fill-finish pharmaceutical contract manufacturing market is anticipated to grow at a CAGR of 5.9% over the forecast years to reach USD 5.2 billion by 2032.
 

• North America is home to several key pharmaceutical companies that require fill-finish services for their products. Further, the region's advanced healthcare infrastructure, strong regulatory framework, and a robust pharmaceutical industry propels the market growth.
   
• Additionally, the region's focus on innovation and technological advancements in pharmaceutical manufacturing further contribute to its leading market position.
   

The U.S. market was valued at USD 2.8 billion in 2023.

• The high market share can be attributed to several factors, including the country's robust pharmaceutical industry, advanced manufacturing capabilities, stringent regulatory standards, and a large pool of skilled workforce.
   
• Additionally, the U.S. market benefits from a strong focus on research and development, which drives the demand for contract manufacturing services. The presence of major pharmaceutical companies and a supportive regulatory environment further contribute to the market's growth and stability.
   

The UK has emerged as a key player in the global market for fill-finish pharmaceutical contract manufacturing, showcasing high growth potential.
 

• The country's strong pharmaceutical industry, supported by a robust regulatory framework and skilled workforce, makes it an attractive destination for contract manufacturing services.
   
• Additionally, the UK's strategic geographical location provides easy access to European markets, enhancing its appeal as a manufacturing hub.
   
• Further, the increasing demand for biologics and personalized medicines boosts the growth potential of the UK's market, positioning it as a key player in the global pharmaceutical manufacturing landscape.
   

China fill-finish pharmaceutical contract manufacturing market is anticipated to witness lucrative growth between 2024 – 2032.
 

• China has emerged as a key player in the market, showcasing high growth potential. Factors such as the country's expanding pharmaceutical industry, advanced manufacturing capabilities, and cost-effective production environment contribute to its growth trajectory.
   
• Additionally, China's favorable regulatory environment attract global pharmaceutical companies seeking high-quality, efficient, and cost-effective manufacturing solutions.
   
• Further, with increasing investments in infrastructure and technology, China is poised to solidify its position as a leading hub for fill-finish pharmaceutical contract manufacturing, offering significant growth opportunities in the coming years.
   

Fill-finish Pharmaceutical Contract Manufacturing Market Share

The fill-finish pharmaceutical contract manufacturing industry is characterized by a diverse mix of players, ranging from multinational corporations to small companies. Large multinational CMOs, such as Boehringer Ingelheim International GmbH, Eurofins Scientific, and Novartis AG dominated a significant portion of the market share. These companies offer comprehensive services, leveraging their global footprint, extensive infrastructure, and diversified service offerings to cater to a wide range of client needs.
 

Fill-finish Pharmaceutical Contract Manufacturing Market Companies

Prominent players operating in the fill-finish pharmaceutical contract manufacturing industry include:

• Boehringer Ingelheim International GmbH
• Catalent Inc
• Eurofins Scientific
• Fresenius Kabi Contract Manufacturing
• MabPlex International Co. Ltd.
• Novartis AG
• Recipharm AB
• Societal CDMO
• Simtra BioPharma Solutions (Baxter International Inc.)
• Symbiosis Pharmaceutical Services
   

Fill-finish Pharmaceutical Contract Manufacturing Industry News:

• In February 2024, Simtra BioPharma Solutions announced expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana. The expansion includes the construction of a new state-of-the-art 150,000 square foot building to house two high-speed automated isolator syringe fill lines and a new high-speed isolator vial line equipped with three 30 square meter lyophilizers. This is aimed to enhance the companies service capabilities thereby attracting more customers.
   
• In July 2021, Recipharm announced investment into a new facility in Uttarakhand, India. This strategic move helped the company increase its fill finish capacity to 1 billion sterile units per year and expand its reach in the Asia Pacific market.
   

The fill-finish pharmaceutical contract manufacturing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Vials
  • Glass vials
  • Plastic vials
• Prefilled syringes (PFS)
  • Glass PFS
  • Plastic PFS
• Cartridges
• Other products

Market, By Molecule

• Large molecules
• Small molecules

Market, By End-use

• Biopharmaceutical companies
• Pharmaceutical companies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa